Effect of a combination of pertuzumab, trastuzumab, and weekly paclitaxel on pCR rates and side-effect profile as a neoadjuvant treatment regimen for HER2-positive breast cancer.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e12652-e12652 ◽  
Author(s):  
Niraj K. Gupta ◽  
Erica Giblin ◽  
Christopher A. Leagre ◽  
Kristen Govert ◽  
Stanley Givens ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Treatment Regimen ◽  
Side Effect ◽  
Neoadjuvant Treatment ◽  
Weekly Paclitaxel ◽  
Side Effect Profile ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

scholarly journals Immune Checkpoint Blockade in HER2-Positive Breast Cancer: What Role in Early Disease Setting?

Cancers ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1655
Author(s):  
Cinzia Solinas ◽  
Debora Fumagalli ◽  
Maria Vittoria Dieci
Keyword(s):  
Breast Cancer ◽  
Immune Checkpoint ◽  
Neoadjuvant Treatment ◽  
Tumor Infiltrating Lymphocytes ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade ◽  
Current Evidence ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

The present commentary synthesizes the current evidence on the role of the immune response in HER2-positive breast cancer. It points out the strengths and weaknesses of the findings observed so far, particularly in the early setting, including the clinical significance of scoring tumor-infiltrating lymphocytes. A figure proposing research hypotheses for the implementation of immune checkpoint blockade use for patient candidates to neoadjuvant treatment is presented.

scholarly journals Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy

2013 ◽  
Vol 2013 ◽  
pp. 1-9 ◽  
Author(s):  
S. Guiu ◽  
M. A. Mouret Reynier ◽  
M. Toure ◽  
B. Coudert
Keyword(s):  
Breast Cancer ◽  
Response Rate ◽  
Neoadjuvant Treatment ◽  
Pathological Response ◽  
Complete Pathological Response ◽  
Her2 Positive ◽  
Major Step ◽  
Her2 Positive Breast Cancer ◽  
Made In ◽  
Positive Breast Cancer

Since 2005, major progresses have been made in the neoadjuvant treatment of HER2-positive breast cancer. Trastuzumab introduction associated with chemotherapy has been the first major step leading to the improvement of the complete pathological response rate and, like in the adjuvant studies, better survivals. Dual HER2 blockade has been the next step and trastuzumab is associated now with other anti-HER2 therapies like lapatinib or pertuzumab, the latter being much more easy to use in combination with chemotherapy. Additional knowledge is necessary to better define within the HER2 tumor subgroup which patients could benefit more from targeted therapies. Different biomarkers have been studied to predict the response after anti-HER2 neoadjuvant therapies but until now none has been validated.

Sign in / Sign up

Export Citation Format

Share Document